Showing results (11-20 of 121) with videos related to

Sort By:
Pageof 13
Pathology International|November 1, 2014
Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1Hui Liu, Zhongwu Li, Yan Wang, et al.
Zhonghua Yi Xue Za Zhi|December 17, 2014
[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma]Lu Si, Xue Bai, Lili Mao, et al.
The Journal of Investigative Dermatology|September 27, 2021
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in MelanomaTianxiao Xu, Jie Dai, Lirui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanomaBin Lian, Lu Si, Chuanliang Cui, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|October 15, 2015
[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule]Chuanliang Cui, Siming Li, Zhihong Chi, et al.
Scientific Reports|January 6, 2017
Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against MelanomaJie Dai, Shan Wu, Yan Kong, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohortLu Si, Yan Kong, Xiaowei Xu, et al.
Oncotarget|February 20, 2016
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisXinan Sheng, Zhihong Chi, Chuanliang Cui, et al.
Thoracic Cancer|March 14, 2019
Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patientsXuan Wang, Yan Kong, Zhihong Chi, et al.
Oncotargets and Therapy|July 27, 2018
<i>TERT</i> copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanomaSifan Yu, Tianxiao Xu, Jie Dai, et al.
Pageof 13